Krilogy Financial LLC Purchases 18,699 Shares of Pfizer Inc. $PFE

Krilogy Financial LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 30.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 80,919 shares of the biopharmaceutical company’s stock after buying an additional 18,699 shares during the quarter. Krilogy Financial LLC’s holdings in Pfizer were worth $1,991,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in PFE. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after acquiring an additional 1,820,634 shares during the last quarter. Norges Bank acquired a new stake in Pfizer during the 2nd quarter worth $2,270,157,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Pfizer by 2.0% in the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after purchasing an additional 950,239 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat and upbeat outlook: Pfizer reported Q4 EPS and revenue above expectations and reiterated a positive forward outlook, which is supporting the rally as investors price in steadier earnings. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Unusual options flow: Elevated call-option activity suggests some traders are positioning for further upside after the results, amplifying short‑term bullish momentum. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Shareholder returns: Management returned $9.8B to shareholders in 2025 (buybacks/dividends), which supports valuation and income-focused investor demand. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders
• Positive Sentiment: Regulatory progress: The FDA granted priority review for HYMPAVZI (marstacimab) sBLA, a pipeline milestone that could add upside if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Neutral Sentiment: Analyst / press commentary: Several outlets (Seeking Alpha, The Motley Fool, Zacks) publish bullish post‑earnings takes and “look again” pieces that may attract retail interest—but these are opinion pieces rather than new company actions. Pfizer: A Great Opportunity Post Earnings
• Neutral Sentiment: One‑time SEC collection: Pfizer will receive $29M related to an SEC matter tied to a 2013 case—positive to cash flow but immaterial to fundamentals. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Negative Sentiment: Patent cliff and pipeline questions: Analysts and commentary warn of a 2026–2030 patent cliff as COVID-era sales wane; questions remain whether new and acquired drugs will offset lost revenue, pressuring longer‑term growth expectations. Can Pfizer’s New & Acquired Drugs Offset Its Looming Patent Cliff?
• Negative Sentiment: Valuation / “value trap” concerns: Critical pieces highlight execution risk and that the stock’s depressed valuation may reflect real growth challenges—these narratives can cap multiple expansion. Is Pfizer Stock Now A Value Trap?

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. TD Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. HSBC reiterated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Finally, Zacks Research lowered shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Price Performance

NYSE PFE opened at $27.74 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The business has a 50 day simple moving average of $25.74 and a 200 day simple moving average of $25.15. The stock has a market cap of $157.70 billion, a price-to-earnings ratio of 20.39 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the company earned $0.63 earnings per share. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.